Literature DB >> 1836445

An ATP-independent complex commits pre-mRNA to the mammalian spliceosome assembly pathway.

S Michaud1, R Reed.   

Abstract

Previous studies have identified five distinct mammalian splicing complexes that assemble on pre-mRNA in vitro. Of these complexes, which include H, E, A, B, and C, only the B and C complexes have been isolated and shown directly to be functional intermediates in the splicing pathway. In this report we carried out a systematic analysis of the temporal and functional relationships among the H, E, A, and B complexes. Using gel filtration to isolate each complex, we show that H complex, which consists primarily of hnRNP proteins, assembles first in either the presence or absence of ATP. Subsequently, E complex, which contains stably bound U1 snRNP, is detected in reactions lacking ATP, whereas A complex, which contains stably bound U1 and U2 snRNPs, is detected in reactions containing ATP. We show that E complex can be chased into A and B complexes and that A complex can be chased into B complex. Both E and A complexes can also be chased into spliced products. In contrast, H complex cannot be chased into A or B complexes or spliced products under the same conditions. We conclude that in addition to the two spliceosome complexes (B and C), two distinct pre-splicesome complexes (E and A) are functional intermediates in the splicing pathway. Comparison of the efficiency of splicesome assembly on different pre-mRNAs has revealed dramatic differences. We show that these differences are first apparent at the time of E complex assembly. Thus, we conclude that E complex commits pre-mRNA to the splicing pathway and that this step is critical in determining the efficiency of mammalian spliceosome assembly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836445     DOI: 10.1101/gad.5.12b.2534

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  144 in total

1.  Resolution of the mammalian E complex and the ATP-dependent spliceosomal complexes on native agarose mini-gels.

Authors:  R Das; R Reed
Journal:  RNA       Date:  1999-11       Impact factor: 4.942

2.  Sequences upstream of the branch site are required to form helix II between U2 and U6 snRNA in a trans-splicing reaction.

Authors:  G Ast; T Pavelitz; A M Weiner
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

3.  PUF60: a novel U2AF65-related splicing activity.

Authors:  P S Page-McCaw; K Amonlirdviman; P A Sharp
Journal:  RNA       Date:  1999-12       Impact factor: 4.942

4.  Prespliceosomal assembly on microinjected precursor mRNA takes place in nuclear speckles.

Authors:  I Melcák; S Melcáková; V Kopský; J Vecerová; I Raska
Journal:  Mol Biol Cell       Date:  2001-02       Impact factor: 4.138

5.  Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion.

Authors:  J Côté; S Dupuis; J Y Wu
Journal:  J Biol Chem       Date:  2000-12-14       Impact factor: 5.157

6.  Yeast U1 snRNP-pre-mRNA complex formation without U1snRNA-pre-mRNA base pairing.

Authors:  H Du; M Rosbash
Journal:  RNA       Date:  2001-01       Impact factor: 4.942

7.  Initial recognition of U12-dependent introns requires both U11/5' splice-site and U12/branchpoint interactions.

Authors:  M J Frilander; J A Steitz
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

8.  Identification of eight proteins that cross-link to pre-mRNA in the yeast commitment complex.

Authors:  D Zhang; M Rosbash
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

9.  Interaction of the U1 snRNP with nonconserved intronic sequences affects 5' splice site selection.

Authors:  O Puig; A Gottschalk; P Fabrizio; B Séraphin
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

10.  An intronic splicing enhancer binds U1 snRNPs to enhance splicing and select 5' splice sites.

Authors:  A J McCullough; S M Berget
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.